No More Red Tape: MHRA Awaits Tougher Sanctioning Powers in the UK
This article was originally published in SRA
Grant Castle and Brian Kelly describe new enforcement powers that will become available to the Medicines and Healthcare products Regulatory Agency once it complies with the principles of the Hampton Report.
You may also be interested in...
Already partnering with AZ and Boehringer Ingelheim in liver targets, the UK biotech sees potential to hit ‘undruggable’ CNS targets as well.
The US agency has announced another month of webinars aimed at labs and manufacturers that are (or have) developed diagnostic tests for the novel coronavirus.
If bad luck comes in threes, GSK will be delighted to see the end of this week with dostarlimab approval delayed, bintrafusp failing in lung cancer and a Phase II of an ulcerative colitis drug discontinued.